Navigation Links
Isis Pharmaceuticals to Present at the 4th Annual Citi Biotech Day
Date:3/25/2009

CARLSBAD, Calif., March 25 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Citi's 4th Annual Biotech Day on Wednesday, April 1, 2009, at 2:00 p.m. ET at the 388 Greenwich Street Conference Center in New York, NY.

A live audio webcast of the presentation will be available on the "Investor Center" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
2. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
3. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
4. Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer
5. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
6. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
7. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
9. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
11. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... During a two ... into a viable company, CereScan’s CEO, John Kelley, joined other Denver business leaders ... and mentor in the Denver area business community, shared his top fundamental learnings ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced ... FDA via 510(k) for sale in the United States. These components expand the ... fusions. With one-level sales beginning in October of 2015, the company has seen ...
(Date:4/28/2016)... 2016 The report "Cryocooler Market ... Service (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, ... to 2022", published by MarketsandMarkets, the global market is ... at a CAGR of 7.29% between 2016 and 2022. ... 94 Figures spread through 159 Pages and in-depth TOC ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... for Connecticut's innovative, growing companies, today announced the launch of VentureClash , ... (fintech) companies. , “VentureClash looks to attract the best early-stage companies ...
Breaking Biology Technology:
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/15/2016)... 15, 2016 --> ... Transparency Market Research "Digital Door Lock Systems Market - Global ... 2023," the global digital door lock systems market in terms ... and is forecast to grow at a CAGR of 31.8% ... and medium enterprises (MSMEs) across the world and high industrial ...
(Date:3/11/2016)... --> --> ... Recognition Market by Technology (Pattern Recognition), by Component (Hardware, ... Type (On-Premises and Cloud), by Industry Vertical and by ... the global market is expected to grow from USD ... 2020, at a CAGR of 19.1%. , ...
Breaking Biology News(10 mins):